Your browser is no longer supported. Please, upgrade your browser.
Chimerix, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own0.20% Shs Outstand62.24M Perf Week13.29%
Market Cap596.41M Forward P/E- EPS next Y-0.75 Insider Trans-10.41% Shs Float51.15M Perf Month79.17%
Income-35.40M PEG- EPS next Q-0.20 Inst Own53.30% Short Float1.74% Perf Quarter234.59%
Sales11.00M P/S54.22 EPS this Y-41.90% Inst Trans0.40% Short Ratio0.88 Perf Half Y155.05%
Book/sh1.34 P/B6.97 EPS next Y-5.60% ROA-33.50% Target Price9.67 Perf Year364.43%
Cash/sh1.37 P/C6.80 EPS next 5Y- ROE-36.50% 52W Range1.19 - 9.66 Perf YTD93.27%
Dividend- P/FCF- EPS past 5Y-2.40% ROI-105.20% 52W High-3.36% Beta1.86
Dividend %- Quick Ratio12.20 Sales past 5Y25.40% Gross Margin- 52W Low684.45% ATR0.73
Employees43 Current Ratio12.20 Sales Q/Q-20.00% Oper. Margin- RSI (14)79.48 Volatility10.22% 9.29%
OptionableYes Debt/Eq0.00 EPS Q/Q85.50% Profit Margin- Rel Volume7.34 Prev Close9.13
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume1.01M Price9.34
Recom2.30 SMA2048.14% SMA5089.94% SMA200180.08% Volume6,623,540 Change2.25%
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-23-16Downgrade Barclays Overweight → Equal Weight $12 → $6
Feb-22-16Downgrade Citigroup Buy → Neutral
Dec-29-15Downgrade JP Morgan Overweight → Neutral $65 → $15
Dec-28-15Reiterated Piper Jaffray Overweight $63 → $10
Dec-28-15Downgrade FBR Capital Outperform → Mkt Perform $73 → $14
Dec-17-15Initiated UBS Buy $55
Oct-05-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15Initiated Citigroup Buy
Aug-18-15Initiated FBR Capital Outperform $73
Aug-06-15Reiterated Brean Capital Buy $50 → $57
May-11-15Reiterated Brean Capital Buy $45 → $50
Mar-04-15Initiated Barclays Overweight $55
Feb-12-15Reiterated Stifel Buy $47 → $57
Dec-31-14Reiterated Brean Capital Buy $33 → $45
Jul-08-14Resumed Brean Capital Buy $33
Jan-20-21 08:03PM  
Jan-19-21 04:19PM  
Jan-11-21 10:29AM  
Jan-08-21 07:48PM  
Jan-06-21 08:00AM  
Dec-22-20 12:41AM  
Dec-12-20 10:30PM  
Dec-08-20 08:56AM  
Dec-07-20 07:00AM  
Nov-07-20 08:33AM  
Nov-06-20 05:50AM  
Nov-05-20 04:01PM  
Oct-29-20 07:00AM  
Oct-28-20 08:12AM  
Sep-13-20 10:21AM  
Sep-10-20 08:00AM  
Aug-10-20 08:25AM  
Aug-03-20 08:00AM  
Jul-15-20 12:22PM  
Jul-05-20 02:43PM  
Jun-22-20 07:00AM  
Jun-18-20 08:00AM  
May-28-20 08:00AM  
May-12-20 06:47AM  
May-07-20 10:25AM  
May-02-20 08:40AM  
Apr-29-20 07:00AM  
Apr-28-20 04:30PM  
Mar-26-20 08:18AM  
Mar-18-20 06:26AM  
Feb-28-20 12:00PM  
Feb-26-20 08:00AM  
Feb-25-20 07:00AM  
Feb-24-20 08:00AM  
Feb-18-20 08:00AM  
Feb-06-20 07:04AM  
Feb-05-20 11:52AM  
Jan-29-20 08:00AM  
Jan-03-20 11:30AM  
Dec-23-19 06:12AM  
Dec-16-19 01:04AM  
Dec-14-19 08:59PM  
Dec-10-19 07:30AM  
Dec-04-19 01:01AM  
Nov-22-19 12:02AM  
Nov-07-19 06:19AM  
Nov-05-19 07:00AM  
Nov-04-19 04:01PM  
Oct-29-19 08:00AM  
Oct-02-19 08:47AM  
Oct-01-19 08:10AM  
Sep-30-19 07:30PM  
Sep-27-19 08:00AM  
Aug-27-19 01:13PM  
Aug-08-19 09:35AM  
Aug-07-19 10:30AM  
Aug-05-19 07:55AM  
Jul-31-19 07:00AM  
Jul-12-19 03:07PM  
Jun-28-19 06:41PM  
May-17-19 08:18AM  
May-16-19 09:11AM  
May-09-19 09:25AM  
May-02-19 04:01PM  
Apr-29-19 10:31AM  
Apr-12-19 01:43PM  
Apr-09-19 11:21AM  
Apr-08-19 05:00PM  
Apr-05-19 02:14PM  
Mar-26-19 06:30PM  
Mar-07-19 12:24PM  
Mar-05-19 07:00AM  
Mar-04-19 08:00AM  
Feb-26-19 08:00AM  
Feb-22-19 08:00AM  
Feb-14-19 08:15AM  
Feb-11-19 07:55AM  
Feb-06-19 02:20PM  
Jan-30-19 11:51AM  
Jan-24-19 10:17AM  
Jan-18-19 06:36AM  
Jan-17-19 09:38AM  
Jan-04-19 07:30AM  
Dec-27-18 09:23AM  
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMSKI MARTHA JDirectorNov 17Option Exercise2.357,04216,5497,042Nov 19 12:57 PM
Jakeman DavidPrincipal Accounting OfficerOct 02Sale2.484,27010,59085,117Oct 02 04:06 PM
Meyer Robert J.DirectorAug 19Buy2.923,50010,22013,500Aug 19 05:34 PM
DEMSKI MARTHA JDirectorAug 10Option Exercise3.161,5845,0051,584Aug 11 05:49 PM
DEMSKI MARTHA JDirectorAug 10Sale3.251,5845,1480Aug 11 05:49 PM
DEMSKI MARTHA JDirectorAug 07Option Exercise3.162,5007,9002,500Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 07Sale3.252,5008,1250Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 06Option Exercise3.162,5007,9002,500Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 06Sale3.292,5008,2240Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 05Option Exercise3.162,5007,9002,500Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 05Sale3.272,5008,1870Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 04Option Exercise3.165,00015,8005,000Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 04Sale3.255,00016,2500Aug 06 12:55 PM
Andriole Michael T.Chief Business OfficerMar 16Buy1.4333,30047,522149,729Mar 17 11:58 AM
MIDDLETON FRED ADirectorMar 12Buy1.4050,00069,900197,523Mar 16 12:19 PM
Sherman Michael A.Chief Executive OfficerMar 12Buy1.4572,995105,653102,995Mar 16 12:51 PM
Nichols GarrettChief Medical OfficerFeb 10Sale1.688,80514,830260,066Feb 11 04:19 PM
Nichols GarrettChief Medical OfficerFeb 07Sale1.702,5504,335268,871Feb 11 04:19 PM
Jakeman DavidPrincipal Accounting OfficerFeb 07Sale1.702,2903,89387,876Feb 11 04:16 PM